Cue Biopharma, Inc. (NASDAQ:CUE) Sees Significant Decrease in Short Interest

Cue Biopharma, Inc. (NASDAQ:CUE) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,000,000 shares, a drop of 6.5% from the November 15th total of 1,070,000 shares. Based on an average daily volume of 762,400 shares, the short-interest ratio is currently 1.3 days.

Cue Biopharma Stock Performance

NASDAQ:CUE opened at $1.06 on Wednesday. The company has a fifty day simple moving average of $1.32 and a two-hundred day simple moving average of $1.05. The company has a market cap of $67.15 million, a price-to-earnings ratio of -1.18 and a beta of 1.66. The company has a quick ratio of 2.22, a current ratio of 2.22 and a debt-to-equity ratio of 0.05. Cue Biopharma has a 52 week low of $0.45 and a 52 week high of $3.20.

Hedge Funds Weigh In On Cue Biopharma

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Cue Biopharma by 7.1% during the first quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after purchasing an additional 150,457 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after purchasing an additional 16,371 shares in the last quarter. Sigma Planning Corp grew its stake in shares of Cue Biopharma by 50.9% during the third quarter. Sigma Planning Corp now owns 401,325 shares of the company’s stock worth $304,000 after purchasing an additional 135,295 shares in the last quarter. Good Life Advisors LLC grew its stake in shares of Cue Biopharma by 23.1% during the third quarter. Good Life Advisors LLC now owns 400,000 shares of the company’s stock worth $303,000 after purchasing an additional 75,000 shares in the last quarter. Finally, GSA Capital Partners LLP grew its stake in shares of Cue Biopharma by 5.1% during the third quarter. GSA Capital Partners LLP now owns 291,663 shares of the company’s stock worth $221,000 after purchasing an additional 14,104 shares in the last quarter. Institutional investors and hedge funds own 35.04% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus dropped their price target on shares of Cue Biopharma from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, August 20th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cue Biopharma presently has an average rating of “Buy” and an average target price of $5.00.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.